Abstract

BackgroundGastrointestinal leiomyosarcomas (LMSs) from intramural smooth muscle are extremely rare, with limited literature. This paper evaluates the epidemiology and survival and prognostic factors in LMSs of the gastrointestinal tract.MethodsClinical data from the Surveillance, Epidemiology and End Results (SEER) 18 registry from 2001 to 2016 with additional treatment fields were compared between primary tumor sites using the chi-squared test for categorical variables and ANOVA for continuous variables. A five-year survival rate analysis was performed for overall and cancer-specific survival. Hazard ratios (HRs) were calculated using univariate and multivariate Cox proportional models using the variables age group, tumor location, grade, stage, surgery, and chemotherapy.ResultsWe identified a total of 523 patients diagnosed with LMSs of the gastrointestinal tract. The median age of diagnosis was 66 years, with no significant difference between tumor sites for age, sex, and race. The five-year overall survival was 77.3%, and the cancer-specific survival was 90.3%. In the multivariate analysis, grade and stage of tumor were the only factors significantly affecting survival in this cohort.ConclusionWhile surgical status significantly affected survival in the univariate analysis, when adjusted for other factors, the HR for death was not significantly different by surgical therapy. Grade 3 tumors and tumors with distant metastasis at diagnosis were associated with worse survival among these patients.

Highlights

  • Leiomyosarcomas (LMSs) make up 10%-20% of all soft tissue tumors and most commonly originate in the uterus, retroperitoneum, and gastrointestinal tract [1]

  • We identified a total of 523 patients diagnosed with LMSs of the gastrointestinal tract

  • We evaluated the overall and cancer-specific survival of LMS using the Surveillance, Epidemiology, and End Results program’s (SEER) 18 registry data from 2001 to 2016 in patients diagnosed with LMS in the gastrointestinal tract using patient demographic data, tumor-specific characteristics, and primary therapy received by the patient

Read more

Summary

Introduction

Leiomyosarcomas (LMSs) make up 10%-20% of all soft tissue tumors and most commonly originate in the uterus, retroperitoneum, and gastrointestinal tract [1]. In 1998, Hirota et al discriminated leiomyosarcomas (LMSs) from gastrointestinal stromal tumors (GISTs) by describing that true LMSs are negative for CD117 (KIT) and CD 34 and positive for smooth muscle actin or desmin [2]. According to the World Health Organization (WHO) Classification of Tumors, 5th Edition of Digestive System Tumors, only 76 gastrointestinal tract LMSs have been reported since 2000. Gastrointestinal leiomyosarcomas (LMSs) from intramural smooth muscle are extremely rare, with limited literature. This paper evaluates the epidemiology and survival and prognostic factors in LMSs of the gastrointestinal tract

Methods
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call